HELSINKI, November 16, 2022. Aplagon Oy (Aplagon), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic agents (APACs) to treat vascular injury related blood vessel occlusions and tissue damage, today announced that it had signed an EIC Accelerator grant agreement (Grant Agreement) with the European Innovation Council and SMEs Executive Agency (EISMEA). Under the Grant […]
HELSINKI, FINLAND and GRONINGEN, THE NETHERLANDS, September 8, 2022. Today, Aplagon Oy (“Aplagon”) announced that it will start its in-human imaging study to visualize the effect of its innovative APAC compound in patients with peripheral arterial occlusive disease / critical limb ischemia. The study will be executed in collaboration with TRACER B.V. (“TRACER”), a CRO […]
HELSINKI, June 7, 2022. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic agents to treat vascular injury related blood vessel occlusions and tissue damage, today announced that its lead pharmaceutical agent, APAC, has been administered for the first time in a clinical study. The Phase 1 clinical study is primarily intended […]
HELSINKI, September 1, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the publication of new data as well as an accompanying commentary by third-party experts in the leading, peer-reviewed Journal of Cardiovascular Pharmacology. The article, “Safety […]
HELSINKI, May 28, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the closing of a EUR 2.2 million funding round. The fundraise was arranged in collaboration with Invesdor Group and was oversubscribed. These funds increase the […]
HELSINKI AND STOCKHOLM, September 19, 2017. Aplagon Oy (“Aplagon”) and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. Under the agreement, Cadila Pharmaceuticals Sweden AB together with its parent company Cadila Pharmaceuticals Limited, […]
